LOS ANGELES--(BUSINESS WIRE)--KYTHERA Biopharmaceuticals, Inc. (“KYTHERA”), a privately-held biotechnology company focused on the development and commercialization of prescription products in aesthetic medicine, presented results from a long-term follow up study assessing persistence of efficacy and post-treatment safety of ATX-101, a first-in-class, injectable drug that is under investigation for the reduction of submental (‘under the chin’) fat. Kevin C. Smith, MD, FAAD, FRCPC presented study results from the first two years of a 5-year follow up on Phase 2A patients at the 2011 Annual Meeting of the American Society for Dermatologic Surgery (ASDS) in Washington, DC.
